Evogene Ltd. (TLV:EVGN)
Israel · Delayed Price · Currency is ILS · Price in ILA 163.00
-0.90 (-0.55%)
Jun 4, 2026, 11:47 AM IDT
Evogene Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1.84 | 3.85 | 5.58 | 2.98 | 1.68 | 0.93 | |
Revenue Growth (YoY) | -72.74% | -30.91% | 87.02% | 78.03% | 80.11% | -10.58% |
Cost of Revenue | 2.71 | 4.09 | 2.38 | 1.49 | 0.91 | 0.77 |
Gross Profit | -0.86 | -0.24 | 3.2 | 1.49 | 0.77 | 0.16 |
Selling, General & Admin | 5.73 | 5.76 | 8.98 | 7.53 | 10.42 | 9.99 |
Research & Development | 7.36 | 7.99 | 12.51 | 16.2 | 20.79 | 21.13 |
Other Operating Expenses | -0.21 | -0.21 | - | - | -3.5 | - |
Operating Expenses | 12.89 | 13.55 | 21.49 | 23.72 | 27.71 | 31.12 |
Operating Income | -13.75 | -13.79 | -18.29 | -22.23 | -26.94 | -30.95 |
Interest Expense | -3.64 | -0.16 | -0.06 | -0.11 | -0.17 | -0.32 |
Interest & Investment Income | - | 0.36 | 0.82 | 0.98 | 0.18 | 0.29 |
Earnings From Equity Investments | -0.08 | -0.04 | -0.04 | - | - | - |
Currency Exchange Gain (Loss) | -0.29 | -0.29 | -0.08 | -0.22 | -1.74 | 1.07 |
Other Non Operating Income (Expenses) | 0.67 | 0.67 | 3.36 | -0.4 | -0.37 | -0.46 |
EBT Excluding Unusual Items | -17.09 | -13.25 | -14.29 | -21.99 | -29.03 | -30.37 |
Merger & Restructuring Charges | - | - | -0.51 | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | 0.05 | -0.72 | -0.06 |
Asset Writedown | -0.25 | -0.25 | - | - | - | - |
Pretax Income | -17.5 | -13.5 | -14.81 | -21.95 | -29.75 | -30.43 |
Income Tax Expense | 0.01 | 0 | 0.01 | 0.02 | 0.09 | 0.01 |
Earnings From Continuing Operations | -17.51 | -13.5 | -14.82 | -21.97 | -29.84 | -30.45 |
Earnings From Discontinued Operations | 6.77 | 5.67 | -3.24 | -3.99 | - | - |
Net Income to Company | -10.73 | -7.83 | -18.05 | -25.95 | -29.84 | -30.45 |
Minority Interest in Earnings | -1.03 | -0.66 | 1.57 | 2.08 | 3.21 | 2.65 |
Net Income | -11.77 | -8.49 | -16.49 | -23.88 | -26.64 | -27.79 |
Net Income to Common | -11.77 | -8.49 | -16.49 | -23.88 | -26.64 | -27.79 |
Shares Outstanding (Basic) | 9 | 8 | 6 | 5 | 4 | 4 |
Shares Outstanding (Diluted) | 9 | 8 | 6 | 5 | 4 | 4 |
Shares Change (YoY) | 40.53% | 38.21% | 24.14% | 10.80% | 2.44% | 43.59% |
EPS (Basic) | -1.37 | -1.08 | -2.89 | -5.20 | -6.43 | -6.87 |
EPS (Diluted) | -1.37 | -1.08 | -2.89 | -5.20 | -6.43 | -6.87 |
Free Cash Flow | -11.29 | -13.64 | -20.33 | -22.15 | -24.85 | -25.56 |
Free Cash Flow Per Share | -1.31 | -1.73 | -3.57 | -4.83 | -6.00 | -6.32 |
Gross Margin | -46.80% | -6.25% | 57.33% | 50.03% | 45.73% | 17.53% |
Operating Margin | -745.66% | -357.85% | -327.95% | -745.51% | -1608.42% | -3328.28% |
Profit Margin | -638.18% | -220.22% | -295.59% | -800.77% | -1590.33% | -2988.49% |
Free Cash Flow Margin | -612.26% | -353.93% | -364.46% | -742.92% | -1483.52% | -2748.71% |
EBITDA | -13.33 | -13.26 | -17.71 | -20.93 | -24.36 | -28.72 |
D&A For EBITDA | 0.42 | 0.52 | 0.58 | 1.3 | 2.58 | 2.23 |
EBIT | -13.75 | -13.79 | -18.29 | -22.23 | -26.94 | -30.95 |